Results 121 to 130 of about 4,121 (170)
Editorial: Advancements in antibody-based immunotherapy and cancer vaccines for hepatocellular carcinoma. [PDF]
Front ImmunolTabll AA +3 more
europepmc +1 more source
Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment. [PDF]
Front OncolMavaei M +7 more
europepmc +1 more source
Next generation targeted non-genotoxic conditioning for hematopoietic stem cell and hematopoietic stem cell-based gene therapy. [PDF]
Front ImmunolOkalova J, Spencer TH, Chandrakasan S.
europepmc +1 more source
Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation. [PDF]
Cancer Biol TherWu Z +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Immunotoxins and nanobody-based immunotoxins: review and update
Journal of Drug Targeting, 2021Immunotoxins (ITs) are protein-based drugs that compose of targeting and cytotoxic moieties. After binding the IT to the specific cell-surface antigen, the IT internalises into the target cell and kills it. Targeting and cytotoxic moieties usually include monoclonal antibodies and protein toxins with bacterial or plant origin, respectively.
Mohammad Reza Khirehgesh +3 more
openaire +2 more sources
Annual Review of Immunology, 1996
The use of immunotoxins (ITs) in the therapy of cancer, graft-vs-host disease (GvHD), autoimmune diseases, and AIDS has been ongoing for the past two decades. ITs contain a targeting moiety for delivery and a toxic moiety for cytotoxicity. Theoretically, one molecule of a toxin, routed to the appropriate cellular compartment, will be lethal to a cell ...
G R, Thrush +3 more
openaire +2 more sources
The use of immunotoxins (ITs) in the therapy of cancer, graft-vs-host disease (GvHD), autoimmune diseases, and AIDS has been ongoing for the past two decades. ITs contain a targeting moiety for delivery and a toxic moiety for cytotoxicity. Theoretically, one molecule of a toxin, routed to the appropriate cellular compartment, will be lethal to a cell ...
G R, Thrush +3 more
openaire +2 more sources
Leukemia Research, 2005
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB(486)IL2, DAB(389)IL2, RFB4 (dsFv ...
Arthur E, Frankel, Robert J, Kreitman
openaire +2 more sources
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB(486)IL2, DAB(389)IL2, RFB4 (dsFv ...
Arthur E, Frankel, Robert J, Kreitman
openaire +2 more sources
Molecular and chemical neuropathology, 1994
Immunotoxins are being tested for the therapy of systemic cancer and brain tumors. Neurotoxicity has been dose limiting for several of these antibody conjugates given systemically. We review the animal and clinical data related to the neurotoxicity of immunotoxins in attempt to understand the molecular basis for the unexpected neural involvement and to
O, Ilercil +5 more
openaire +2 more sources
Immunotoxins are being tested for the therapy of systemic cancer and brain tumors. Neurotoxicity has been dose limiting for several of these antibody conjugates given systemically. We review the animal and clinical data related to the neurotoxicity of immunotoxins in attempt to understand the molecular basis for the unexpected neural involvement and to
O, Ilercil +5 more
openaire +2 more sources
Breast Cancer Research and Treatment, 1996
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
I, Pastan +3 more
openaire +2 more sources
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
I, Pastan +3 more
openaire +2 more sources